RMD Open
Rheumatic & Musculoskeletal Diseases

ORIGINAL RESEARCH

Surgical denervation as a treatment strategy for pain in hand osteoarthritis: a systematic literature review

Coen van der Meulen ,[1] Lotte A van de Stadt,[2] Aniek Claassen,[3] Féline P B Kroon ,[4] Marco J P F Ritt,[5] Frits R Rosendaal,[6] Sietse E S Terpstra ,[1] Anne J H Vochteloo,[7] Margreet Kloppenburg[1]

To cite: van der Meulen C, van de Stadt LA, Claassen A, *et al*. Surgical denervation as a treatment strategy for pain in hand osteoarthritis: a systematic literature review. *RMD Open* 2023;**9**:e003134. doi:10.1136/rmdopen-2023-003134

► Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/rmdopen-2023-003134).

Received 7 March 2023
Accepted 17 July 2023

For numbered affiliations see end of article.

Correspondence to
Coen van der Meulen;
C.van_der_meulen@lumc.nl

ABSTRACT

Objective Surgical denervation has been proposed as a treatment for pain in hand osteoarthritis (OA). This review aimed to summarise the available evidence and to propose a research agenda.

Methods A systematic literature search was performed up to September 2022. Two investigators independently identified studies that reported on denervation for OA of the proximal interphalangeal, distal interphalangeal, metacarpophalangeal or carpometacarpal joints. Quality of studies was assessed and study characteristics, patient characteristics, details of the surgical technique and outcomes of the surgery were extracted.

Results Of 169 references, 17 articles reporting on 384 denervations in 351 patients were selected. Sixteen case series reported positive outcomes with respect to pain, function and patient satisfaction. One non-randomised clinical trial reported no difference in outcome when comparing denervation of the first carpometacarpal (CMC I) joint to trapeziectomy. Adverse events were frequent, with sensory abnormalities occurring the most, followed by the need for revision surgery. All studies had significant risk of bias.

Conclusion Surgical denervation for pain in hand OA shows some promise, but the available evidence does not allow any conclusions of efficacy and higher-quality research is needed. Techniques should be harmonised and more data regarding how denervation compares to current usual care, other denervation methods or placebo in terms of outcomes and adverse events are needed.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Pain is a core symptom of hand osteoarthritis, which often cannot be fully alleviated with current treatment options. Surgical denervation has been proposed as a treatment option.

WHAT THIS STUDY ADDS

⇒ Surgical denervation may yield favourable outcomes, but evidence on surgical denervation is still insufficient to make a recommendation.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Future research should focus on (1) the innervation of the joints, (2) the best technique for surgical denervation, (3) high-quality randomized clinical trials investigating efficacy of surgical denervation versus sham or (4) comparing surgical denervation to alternative treatments and (5) the safety of surgical denervation.

INTRODUCTION

Hand osteoarthritis (OA) is a common disease which causes loss of function, structural damage to the joints and, most importantly, pain.[1 2] As there are currently no disease-modifying treatments, therapy is aimed at symptom control. Current guidelines of the European Alliance of Associations for Rheumatology and American College of Rheumatology (ACR) recommend non-pharmacological treatment first (eg, education, training, braces).[3 4] Topical or systemic treatments with non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for pain alleviation, with a preference for topical treatment due to the considerable toxicity of oral NSAIDs for elderly patients. For patients with structural abnormalities and inadequate pain control, surgery consisting of trapeziectomy with or without interposition and/or suspension arthroplasty (first carpometacarpal (CMCJ-I)), arthrodesis or arthroplasty (proximal interphalangeal joint (PIPJ) and distal interphalangeal joint (DIPJ)) is recommended as the last resort. The recommended therapies can also be combined.[3 4]

Alternatively, treatment can target the nerves, disturbing the transmission of pain signals through nerves innervating the joint. An example is radiofrequency ablation, which is conditionally recommended by the ACR guidelines for knee OA.[3] Surgical

denervation, that is, the surgical dissection of nerves, can theoretically achieve the same goal as ablation. It was originally described in the hip and later developed for the hand and wrist,[5–7] and has been proposed as an alternative surgical intervention.[5 8–10] Currently, surgical denervation is increasingly being performed to treat pain in hand OA, although precise numbers are unclear.

Surgical denervation aims to dissect the nerves innervating the painful joint, thereby disabling the pain signalling without impairing joint function. Surgical denervation does not seem to be associated with a loss of function or strength, and it does not preclude further surgeries if required, which is advantageous compared with other surgical options.[9 10] However, some downsides have to be taken into consideration. For the denervation to be effective, anatomical knowledge of the joints of the hand and their innervation is essential. The nerves currently known to innervate the hands are summarised in online supplemental appendix 1.[11–15] The innervation of the joints in the hands is still subject to debate and more nerve branches than the ones currently treated with surgical denervation may contribute to the innervation of specific joints.[11] Furthermore, the occurrence of adverse effects has been reported, including wound infection, necrosis of skin flaps, or sensory abnormalities.[9 10]

It is currently unclear whether the advantages of surgical denervation outweigh the disadvantages. We performed a systemic literature search, aiming to summarise available evidence on the efficacy and safety of denervation as a treatment for hand OA compared with other treatments, and to set a research agenda.

METHODS

Search strategy

A systematic literature search was conducted in PubMed, Ovid and Cochrane databases from their inception up to 21 September 2022, with additional references collected from the identified publications and other systematic literature reviews. The search strategies consisted of terms for “hand”, “osteoarthritis” and “denervation” and can be found in online supplemental appendix 2.

Eligible study types were randomised clinical trials, case–control studies, cohort studies, case reports and case series. Studies on OA in other joints (including wrist) or other causes of hand pain were excluded. Studies regarding interventions other than surgical denervation were similarly excluded. Reviews, comments and editorials, as well as abstracts without a full publication, were considered ineligible for review, but have been used to gather more suitable articles from the references.

Studies of surgical denervation (intervention) in adults with hand OA (population) were included. Hand OA comprised OA or degenerative arthritis of the DIPJ, PIPJ, CMCJ-I or metacarpophalangeal joint (MCPJ). The comparator could be any other treatment for hand OA, or none, in the case of case studies. No requirements were set for the outcome measures.

Study selection, data extraction and risk of bias assessment

Two reviewers (CvdM and AC) independently screened titles and abstracts to determine eligibility for inclusion. Screening results were compared and discussed in case of disagreement. Relevant data on study characteristics, interventions (denervated joint, nerves dissected, incisions used, postoperative care), study population (sample size, diagnostic criteria, demographics and baseline characteristics) and outcomes (pain and function scores after surgery, patient satisfaction, follow-up time, strength, adverse events) was extracted (CvdM) and summarised as average and/or range. The risk of bias was assessed (CvdM and SEST). For case series the Joanna Briggs Institute (JBI) checklist for case series was used, judging studies based on inclusion, diagnosis and classification of condition, reporting of demographic, clinical and outcome information, and statistical analysis.[16] The ROBINS-I was used for comparative studies, judging on confounding, selection bias, classification and adherence to intervention, missing data, outcome measurements and selective reporting.[17]

Some of the JBI checklist items required further specification. The following definitions have been used. For the measurement of the severity of the condition to be standard and reliable, it was required to be identical for all patients and be reproducible. The use of any validated clinical or radiological system was deemed valid. For diagnosis, a validated radiological or clinical system was similarly required. Consecutive and complete inclusion of patients was judged on whether this was explicitly stated in the paper. Clear reporting of the demographics of the patients was defined as clear presentation of at least age and sex.

The risk of bias assessments were performed independently by the two reviewers, after which the outcomes were compared. In case of disagreement, the item was discussed to reach consensus. In case no consensus was reached, it was discussed with a third reviewer (MK).

The level of evidence of the individual studies was rated according to the Oxford Centre for Evidence-Based Medicine levels of evidence by CvdM.[18]

No review protocol was registered.

RESULTS

Searching PubMed, Ovid and Cochrane databases yielded 212 records. After deduplication, 169 publications remained. Screening of titles and abstracts resulted in 27 records. After full-text screening, another 13 were excluded (1 due to an unclear patient group, 12 due to type of publications). References from retrieved publications included three suitable records, leading to a total of seventeen records included (figure 1).



Figure 1 Flowchart of literature search.

Study characteristics

The included studies consisted of sixteen case series and one non-randomised comparative clinical trial. Studies are summarised in table 1. Most publications (n=11) described CMCJ-I denervation. MCPJ (n=1), DIPJ (n=1) and PIPJ (n=3) denervation were less frequent. One case series described a mixture of MCPJ, DIPJ and PIPJ denervation. A total of 384 denervations were performed in 351 patients. Twelve of these patients were described in two publications (Suresh *et al*[19] and Tuffaha *et al*[20]). Furthermore, overlap between the patient groups in the two publications by Ehrl *et al*[21 22] could not be excluded.

In seven of the case series, OA was diagnosed based on clinical presentation. In two a clinical diagnosis confirmed by radiography was used, in four only radiography was used. Among these four, the Eaton-Littler criteria were used in two, the Dell criteria in one and no criteria were specified in one. The method of diagnosing OA was not specified in four publications. Inclusion and/or exclusion criteria were specified in 12 publications and often included failure on conservative treatment, some description of radiological damage, response to nerve block or mobility of the joint. Previous joint surgery was used as an exclusion criterion in the majority of studies.

The non-randomised trial described a comparison of trapeziectomy to CMCJ-I denervation. Ten participants were included in the trapeziectomy arm, 35 were included in the denervation arm. Diagnosis was clinical. Inclusion criteria consisted of thumb base OA requiring surgery, with no prior surgery. For details, see table 1.

Methodological quality of included studies

Table 2 describes the methodological quality of the 16 case series. Most had clear inclusion criteria, but only in a few presence and severity of hand OA were measured in a reliable and standard way, with the assessment often not described or based on clinical judgement. Clinical assessment and radiographic staging, or a combination, were most frequently used. Radiographs were scored using either the Dell (n=1), Eaton-Littler (n=3) or unspecified (n=2) criteria. Seven reports stated inclusion had been complete, with five stating it had

Table 1 Study characteristics

Author, publication year	Patients (n); joints	OA diagnosis criteria	Additional intervention	Relevant inclusion and exclusion criteria	LoE
Case series					
CMCJ-I					
Arenas-Prat 2012[34]	16; 18	N/A	None	N/A	IV
Arenas-Prat 2022[28]	17; 17	N/A	None	N/A	IV
Dellon 2017[27]	3; 3	Radiological	None	Inclusion: volar osteophyte on radiograph, positive grind test, no response to conservative treatment	IV
Donato *et al* 2019[24]	8; 11	Clinical	None	Inclusion: ≥6-month follow-up, good response to bipuvacaine block. Exclusion: incomplete preoperative testing or follow-up	IV
Ehrl *et al* 2016[21]	42; 42	Radiological (Eaton-Littler)	Lavage and imbrication	Inclusion: no sustained benefits from conservative treatment, including ≥1 steroid injection. Exclusion: prior surgery, Eaton-Littler stages I or IV	IV
Ehrl *et al* 2016[22]	60; 60	Radiological (Eaton-Littler)	Lavage and imbrication	Inclusion: no sustained benefits from conservative treatment, including ≥1 steroid injection. Exclusion: prior surgery, Eaton-Littler stages I or IV	IV
Giesen *et al* 2017[26]	30; 31	Radiological (Dell)	None	Inclusion: no Z-deformity, primary CMCJ-I OA	IV
Loréa 2003[25]	14; 14	Clinical	None	Inclusion: OA	IV
Suresh *et al* 2023[19]	12 (3 lost to follow-up); 12	Clinical and radiological (Eaton)	None	Inclusion: symptomatic OA	IV
Tuffaha *et al* 2019[20]	12; 12	Clinical	None	Inclusion: good response to block at median nerve in mid-forearm or around joint capsule	IV
PIPJ					
Braga-Silva and Calcagnotto 2001[32]	21; 24	Clinical	None	N/A	IV
Jiménez *et al* 2020[31]	11; 11	Clinical and radiological	None	Inclusion: painful, disabling OA, resistant to conservative treatment, RoM >30°, good lateral joint stability	IV
Servasier *et al* 2021[29]	42; 54	Clinical	None	Inclusion: pain with functional RoM (60° passive)	IV
DIPJ					
Arenas-Prat 2012[33]	10; 10	N/A	None	N/A	IV
MCPJ					
Arenas-Prat 2014[35]	9; 9	N/A	None	N/A	IV
MCPJ/DIPJ/PIPJ					
Madsen *et al* 2018[30]	11; 23	Clinical	None	Inclusion: painful OA with preserved motion, inadequately controlled with NSAIDs	IV
Non-randomised clinical trial					
CMCJ-1					
Salibi *et al* 2019[23]	45; 45	Clinical	None	Inclusion: OA requiring surgery. Exclusion: previous surgery	II

CMCJ-I, First carpometacarpal joint ; DIPJ, distal interphalangeal joint; LoE, level of evidence; MCPJ, metacarpophalangeal joint; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; PIPJ, proximal interphalangeal joint; RoM, range of motion.

Table 2 Risk of bias assessment

Joint	Study	Joanne Briggs institute checklist for case series criteria									
		Clear inclusion criteria?*	Standard measurement of condition?†	Valid identification methods for condition?‡	Consecutive inclusion of patients?§	Complete inclusion of participants?¶	Clear reporting of patient demographics?**	Clear reporting of clinical information of patients?††	Outcomes or follow-up clearly reported?‡‡	Clear reporting of demographics of clinic?§§	Statistical analysis appropriate?¶¶
CMCJ-I	Arenas-Prat 2012[34]	N	U	U	U	U	N	N	N	N	N
	Arenas-Prat 2022[28]	N	U	U	Y	Y	N	N	N	N	N
	Dellon 2017[27]	Y	N	N	U	N	Y	Y	Y	N	N
	Donato *et al* 2019[24]	Y	U	U	Y	Y	Y	Y	Y	N	Y
	Ehrl *et al* 2016[21]	Y	Y	Y	U	N	Y	Y	Y	N	N
	Ehrl *et al* 2016[22]	Y	Y	Y	U	N	Y	Y	Y	N	N
	Giesen *et al* 2017[26]	Y	Y	Y	U	Y	Y	Y	Y	N	N
	Loréa 2003[25]	Y	U	U	Y	Y	N	N	Y	N	N
	Suresh *et al* 2023[19]	Y	Y	Y	Y	Y	Y	N	N	N	Y
	Tuffaha *et al* 2019[20]	Y	Y	Y	N	N	Y	Y	Y	N	N
PIPJ	Braga-Silva and Calcagnotto 2001[32]	N	N	U	U	Y	Y	Y	Y	N	N
	Jiménez *et al* 2020[31]	Y	N	N	U	U	Y	Y	Y	N	Y
	Servasier *et al* 2021[29]	Y	N	N	U	U	Y	Y	Y	N	Y
DIPJ	Arenas-Prat 2012[33]	N	U	U	U	U	N	N	N	N	N
MCPJ	Arenas-Prat 2014[35]	N	U	U	U	U	N	N	N	N	N
mixed	Madsen *et al* 2018[30]	Y	N	N	Y	Y	Y	Y	Y	N	Y

Continued

Table 2 Continued

Joint	Study	Joanne Briggs institute checklist for case series criteria									
		Clear inclusion criteria?*	Standard measurement of condition?†	Valid identification methods for condition?‡	Consecutive inclusion of patients?§	Complete inclusion of participants?¶	Clear reporting of patient demographics?**	Clear reporting of clinical information of patients?††	Outcomes or follow-up clearly reported?‡‡	Clear reporting of demographics of clinic?§§	Statistical analysis appropriate?¶¶

Risk of bias assessment according to the Joanne Briggs Institute checklist for case series.
*Were there clear criteria for inclusion in the case series?
†Was the condition measured in a standard, reliable way for all participants included in the case series?
‡Were valid methods used for identification of the condition for all participants included in the case series?
§Did the case series have consecutive inclusion of participants?
¶Did the case series have complete inclusion of participants?
**Was there clear reporting of the demographics of the participants in the study?
††Was there clear reporting of clinical information of the participants?
‡‡Were the outcomes or follow-up results of cases clearly reported?
§§Was there clear reporting of the presenting site(s)/clinic(s) demographic information?
¶¶Was statistical analysis appropriate?
CMCJ-I, First carpometacarpal joint; DIPJ, distal interphalangeal joint; MCPJ, metacarpophalangeal joint; N, no; NA, not applicable; PIPJ, proximal interphalangeal joint; U, unclear; Y, yes.

been consecutive. Demographic and clinical characteristics, as well as outcomes, were often presented clearly, although often few characteristics were given. None of the studies reported the demographic information of the study centre (geographic location, setting of the centre). Finally, in 11 of the case series, the statistical analysis was either absent (n=6) or inappropriate (n=5). All reviewed case series therefore had severe methodological shortcomings.

The clinical trial by Salibi *et al*[23] had serious risk of bias in multiple domains: it was an open label study, a substantial proportion of participants switched interventions from denervation to trapeziectomy and were subsequently removed from the analysis, and confounding was not taken into account in the analysis. For an overview, see online supplemental appendix 3 table A2.

Surgical techniques

The studies used a variety of techniques, summarised in table 3.

CMCJ-I denervation

Most studies used a single incision, either a Wagner approach (online supplemental figure A1), a transverse incision (online supplemental figure A2) or a radial S-shaped incision (online supplemental figure A3). Two groups (Donato *et al*[24] and Loréa[25]) used two incisions: a palmar and a dorsal transverse incision (online supplemental figures A4 and A5). Giesen *et al*[26] added a third incision in the fourth extensor compartment (online supplemental figure A6).

Which nerves were dissected differed between studies. Two studies did not specify the dissected nerves and one only stated that all branches leading to the joint capsule were dissected.[23 27] The other nine studies all reported dissecting of branches from the radial nerve (extending from the radial sensory nerve or the superficial branch of the radial nerve), the medial nerve (from the thenar, palmar or palmar cutaneous branches) and the lateral antebrachial cutaneous nerve (from the Cruveilhier branch, or without further specification of smaller branches). Giesen *et al*[26] additionally dissected the posterior interosseous nerve, Donato *et al*[24] and Loréa[25] a small part of the dorsal articular nerve of the first interosseous space.

Four groups added additional procedures during the surgery: Dellon[27] injected the nerve endings with lidocaine and removed volar osteophytes, Ehrl *et al*[21 22] performed synovectomy and excised osteophytes, followed by saline irrigation of the joint. Arenas-Prat[28] performed periosteal resection of the first metacarpal and Suresh *et al*[19] report anaesthesia with lidocaine of articular branches.

PIPJ denervation

Several incision techniques were used. A Brunner incision was used in all four studies investigating PIPJ denervation (online supplemental figure A7). Among the four,

Table 3 Details surgical interventions

Author	Incision; figure	Nerves dissected	Additional intervention	Postoperative care
Case series				
CMCJ-I				
Arenas-Prat 2012[34]	Wagner; A1	Articular branches of SBRN, PBMN, TBMN, CBLACN	None	Mobilisation as pain allows after 2 weeks
Arenas-Prat 2022[28]	Wagner; A1	SBRN, PBMN, TBMN and CBLACN	Periosteal resection of first metacarpal	Soft bandage with splint for 2 weeks. Gradual mobilisation after 2 weeks
Dellon 2017[27]	Transverse at base of first metacarpal; A2	Unclear	Nerve injected with 1% lidocaine. Volar osteophyte removed	Return to activities over 2 weeks after 1 week
Donato *et al* 2019[24]	Palmar transverse; A4 first interosseous space; A5	Articular branches of radial nerve, SBRN, PCBMN, TBMN, CBLACN. Dorsal articular nerve of the first interosseous space	None	No activity restrictions
Ehrl *et al* 2016[21]	Radial S shaped incision; A3	Dorso-radial and dorso-ulnar sensory branches from radial nerve to thumb, CBLACN, branches of PCBMN	Synovectomy and excision of osteophytes, joint irrigated normal saline	Plaster cast for 2 weeks, then splint for 2 weeks
Ehrl *et al* 2016[22]	Radial S shaped incision; A3	Dorso-radial and dorso-ulnar sensory branches from radial nerve to thumb, CBLACN, branches of PCBMN	Synovectomy and excision of osteophytes, joint irrigated normal saline	Plaster cast for 2 weeks, then splint for 2 weeks
Giesen *et al* 2017[26]	Transverse palmar; A4 first interosseous space; A5 Fourth extensor compartment; A6	Articular branches of SBRN, PBMN, TBMN, CBLACN, PIN	None	N/A
Loréa 2003[25]	Transverse palmar; A4 Dorsal in first interosseous space; A5	Articular branches of the SBRN, PBMN, TBMN, CBLACN, nerve of the first interosseous space	None	Rest for 3 weeks. Gradual resuming of normal activities after that
Suresh *et al* 2023[19]	Wagner; A1	Branches from LABCN, SBRN, PCBMN	Intraepineural 1% lidocaine of nerves	Hand therapy and increasing activity over 5–12 days
Tuffaha *et al* 2019[20]	Wagner; A1	Articular branches from RSN, LABCN, PCBMN	None	N/A
PIPJ				
Braga-Silva and Calcagnotto 2001[32]	Volar Brunner; A7	Articular branches of palmar digital nerves	None	Early active mobilisation of digits
Jiménez *et al* 2020[31]	Brunner; A7	Articular branches of common digital nerve, dorsal digital nerves	None	Active mobilisation after 5 days

Continued

Table 3 Continued

Author	Incision; figure	Nerves dissected	Additional intervention	Postoperative care
Servasier *et al* 2021[29]	4 as Foucher; A7 12 as Lorea; A8 38 with single dorsal on PIPJ; A9	All joint afferents	None	N/A
DIPJ				
Arenas-Prat 2012[33]	From eponichium to joint; A10	Articular branches of volar and dorsal digital nerves	None	Mobilisation as pain allows after 2 weeks
MCPJ				
Arenas-Prat 2014[35]	Volar Brunner; A11 Dorsal straight; A13	Articular branches of dorsal digital nerve, volar digital nerves, DBUN	None	Mobilisation as pain allows after 2 weeks
MCPJ/DIPJ/PIPJ				
Madsen *et al* 2018[30]	MCPJ: Volar Chevron; A12. Dorsal linear; A13 PIPJ: Brunner; A7. DIPJ: U shaped flap to eponychium; A10	MCPJ: branches from radial and ulnar digital nerves. Articular branches of RSN or DSBUN. PIPJ: radial, ulnar and dorsal digital nerve branches. DIPJ: branches from digital nerves	None	Movement and use of hand as possible encouraged. Return to activity as tolerated
Non-randomised clinical trial				
CMCJ-I				
Salibi *et al* 2019[23]	Dorsoradial; A3	All branches leading to joint capsule	None	N/A

Surgical techniques used.
Incisions: Wagner incision=slightly curved incision across the thenar eminence, towards the palmar aspect (online supplemental figure A1). Brunner incision=Zigzag incision across the palmar side of the finger (online supplemental figure A10).
CBLACN, Cruveilhier branch from lateral antebrachial cutaneous nerve; CMCJ-I, First carpometacarpal joint ; DANFIS, dorsal articular nerve of the first interosseous space; DBUN, deep branch of ulnar nerve; DIPJ, distal interphalangeal joint; DSBUN, dorsal sensory branch of ulnar nerve; LABCN, lateral antebrachial cutaneous nerve; MCPJ, metacarpophalangeal joint; MRMN, median recurrent motor nerve; N/A, not available; PBMN, palmar branch of median nerve; PCBMN, palmar cutaneous branch of median nerve; PIN, posterior interosseous nerve; PIPJ, proximal interphalangeal joint; RSN, radial sensory nerve; SBRN, superficial branch of radial nerve; TBMN, thenar branch of median nerve; UMN, ulnar motor nerve.

only Servasier *et al*[29] also used other approaches: a double lateral (online supplemental figure A8) or straight incision on the dorsal aspect of the joint (online supplemental figure A9).

Again, the specific nerves that were dissected varied. Servasier *et al*[29] stated they dissected all joint afferents, Madsen *et al*[30] dissected the articular branches of the radial, ulnar and dorsal digital nerves, Jiménez *et al*[31] dissected the palmar articular nerve, and the articular branches of the common and dorsal digital nerves, and Braga-Silva and Calcagnotto[32] dissected the branches from the palmar digital nerves.

DIPJ denervation

A skin flap extending from the eponichium to the joint was used in both studies on DIPJ denervation (online supplemental figure A10). Both described dissecting the articular branches of the digital nerves, with Arenas-Prat[33] specifying the volar and dorsal digital nerves.

MCPJ denervation

MCPJ denervation was done using two incisions in both studies describing it: a volar Brunner (online supplemental figure A11) or Chevron incision (online supplemental figure A12) and a dorsal linear incision (online supplemental figure A13). Both groups dissected articular branches of the digital nerves (dorsal and volar for Arenas-Prat,[34] radial and ulnar by Madsen *et al*[30]), Arenas-Prat further dissected the branches from the deep branch of the ulnar nerve. Madsen *et al* dissected the branches from the digital branch of the radial sensory nerve and the dorsal sensory branch of the ulnar nerve.

Postoperative care

When described, most recovery plans were comparable: gentle return to activities as pain allows, with the main difference between studies being the time before return to activities (0–3 weeks).

Patient characteristics and outcomes

Baseline characteristics

The studies encompassed a patient group with average age from 55 to 65 years (range 30–87 years) (table 4). The study by Jiménez *et al*[31] stood out, having a population with a lower median age (52 years). The percentage of female participants was around 60%–75% in most studies, with a very high percentage (98%) in the study by Servasier *et al*,[29] and a very low percentage (36%) in the study by Jiménez *et al*.[31]

Most studies presented baseline pain scores, often on a 0–10 Numeric Rating Scale (NRS). Average baseline pain scores varied from 7.5 to 8.7 on NRS. Giesen *et al*[26] split the baseline scores into pain at rest, light activity and demanding activity. They reported median pain scores of 5, 7.5 and 10, respectively. Madsen *et al*[30] used a 5-point scale, reporting a median of 5/5 (table 4).

Of note, the study by Servasier *et al*[29] included arthropathies of various types: degenerative (43 joints) and inflammatory (11 joints). Inflammatory was further divided into rheumatoid arthritis (seven joints), ankylosing spondylarthritis (one joint), psoriatic arthritis (two joints) and undetermined inflammatory rheumatism (one joint).

Follow-up

Fifteen out of seventeen studies reported the follow-up duration, which ranged from 4 to 152 months. In most studies, a physical follow-up was used, with the exception of the study by Ehrl *et al*,[22] in which 23 of the 60 patients only had a follow-up over the telephone, and Giesen *et al*,[26] where the final follow-up consisted of a questionnaire only, with a physical follow-up halfway through the follow-up period.

Outcomes

Fifteen of the seventeen groups reported postoperative pain outcomes, using a Visual Analogue Scale (VAS) or NRS, or using their own scales or descriptions. Almost all studies reported good results, with 56%–92% patients experiencing some measure of pain relief.[19 20 24 25 34 35] The mean change in NRS score ranged from 3 to 8.1 on a 10-point scale.[21 22 24 26 27 29–32] Salibi *et al*[23] reported no differences in pain when comparing denervation to trapeziectomy from baseline to months 6, 12 and 60.

Fifteen out of seventeen studies reported other outcome measures. Six reported on patient satisfaction, which ranged from 70% to 92%.[24 28 32–35] Three studies reported on range of motion of the joint after surgery; mean increase ranged from 3.5° to 27°.[29 31 32] Three other studies reported on grip strength, with average increase around 3.9 kg[20 26] or 12 foot/lb[24] for grip strength and 2.1 kg for pinch grip strength.[20 26] Finally, various questionnaires and other physical examinations were reported; most showing beneficial results.[19 21 22 26 30 31] For details, see table 4.

Adverse events

Rates of adverse events varied between 0% and 75% (table 4).[20–22 24–34] Most studies (n=9) reported rates of 20% or lower. The most frequently occurring complications were (temporary) sensory disturbances, such as pain, paraesthesia or numbness.[20–22 24–26 28–34] Other reported complications included wound infection, skin necrosis and complex regional pain syndrome type I.[21 22 24 29 34] Three studies (by Salibi *et al*, Suresh *et al* and by Servasier *et al*[19 23 29]) reported numbers of patients undergoing an additional type of surgery due to dissatisfaction. In the study by Salibi *et al* 9 out of 35 (26%) underwent a trapeziectomy, Servasier *et al* reported 7 out of 54 (13%) joints underwent either arthrodesis (n=2) of arthroplasty (n=5), Suresh *et al* reported 3 out of 9, which underwent arthroplasty.

DISCUSSION

Pain in hand OA remains difficult to treat, and new therapies are required. Surgical denervation has been proposed as an option. In this review, we gave an overview of the available literature describing the efficacy and safety of surgical denervation for OA in the PIPJ, DIPJ, MCPJ and CMCJ-I. No meta-analysis was performed due to the heterogeneity of the surgical techniques and the reported outcome measures.

The overall quality of the evidence was low. Most studies were case series (with the inherent shortcoming that there was no blinding or randomisation) and all studies had methodological shortcomings. Most common were lack of clarity regarding the inclusion of patients (consecutive or not, stringency of diagnosis, use of diagnostic criteria) and statistical analysis of the results. Despite the fact that most included studies were case series, these shortcomings still stand out and therefore the results of these studies may be biased. The varying use of diagnostic criteria hampers generalisability. Furthermore, properly performed randomised clinical trials were unavailable, precluding adequate comparison to other (non)pharmacological treatments or surgical methods, as well as comparison to usual care or sham. In particular, it would be valuable to have trials comparing surgical denervation to other interventions targeting nerves, such as for example, radiofrequency ablation. Ablation (using radiofrequency or cryoneurolysis) is conditionally recommended by the ACR guidelines for knee OA,[3] based on two randomized clinical trials (RCTs) comparing it to sham[36 37] and two RCTs comparing it to intra-articular injection with corticosteroids[38] or platelet rich plasma and hyaluronic acid,[39] as well as one comparing it to oral analgesics.[40]

The trial by Salibi *et al*[23] started out as randomised, but diverted from this design due to slow inclusion, which

Table 4 Patient characteristics and outcomes

First Author	Patient age years (range); female sex (%)	Baseline pain	Follow-up (months)	Outcomes at follow-up		Adverse events (number of joints)
				Pain	Other	
Case series						
CMCJ-I						
Arenas-Prat 2012[34]	N/A; N/A	N/A	N/A	N/A	14/16 patients, 16/18 joints, very satisfied	Hypertrophic scar (2) Hypoesthesia (1)
Arenas-Prat 2022[28]	N/A; N/A	N/A	4–6*	N/A	15/17 satisfied/very satisfied	Mild paraesthaesia (4)
Dellon 2017[27]	64.3 (54–83)†; N/A	8.7‡	125.6 (48–152)†	0.67‡; average ↓8.1 on NRS	N/A	None
Donato *et al* 2019[24]	63.4 (55–77)†; 62.5	7.9 (2.3)§	18.5 (7–30)†	1.9 (1.9)§; average ↓6 on NRS 7/8 patients reported improvement	Grip strength: 50.2 (10–99)†; average ↑11.8 87.5% patient satisfaction	Wound infection (1) Persistent focal pain (1)
Ehrl *et al* 2016[21]	62.7 (47–81)†; 81	7.5 (1.6)§	46.5 (6–82)†	1.1 (1.1)§; average ↓6.4 NRS	DASH 18.1 (1.3)§; average ↓28.7 Cooney 73.7 (16.0)§; average ↑38.3 Krimmer 80.0 (14.1)§; average ↑41.7	Postoperative wound infection (1) Complex regional pain syndrome (1)
Ehrl *et al* 2016[22]	Physical: 63 (10)§; 78 Phone: 61 (11)§; 70	7.5 (1.6)§	Physical: 46 (12–81)† Phone: 52 (14–93)†	Telephone FU: 87% improved complaints, 45% no complaints. Physical FU: 1.1 (1.4)§; average ↓6.4	DASH 18.4 (14.9)§ Cooney71.6 (15.7)§ Krimmer 79.1 (13.7)§ Subjective weakness/ stiffness ↓	Postoperative wound infection (1) Complex regional pain syndrome (1)
Giesen *et al* 2017[26]	62 (39–86)†; 73	At rest: 5 (5).¶ Gentle activity: 7.5 (1.5)¶ Heavy activity: 10 (2.5)¶	12	6 months: improved 12 months: At rest: 2 (3)¶ Gentle activity: 5.0 (3.8)¶ Demanding activity: 6.0 (4.0)¶	6 months: Key-pinch ↑2.5 (2.1)§ kg Grip strength ↑ 3.6 (6.0)§ Kapandji score 9.3 (0.6)§; average ↑0.8 12 months: Kapandji score improved 1–2 points in 50% of cases	Paraesthesia of SBRN (3) Mild neuropathic pain >2 years (1) Mild synovitis, resolved with 1 month of splinting (1)
Loréa 2003[25]	60 (30–77)†; N/A	N/A	8 (12)††	12/14>80% ↓ pain. 1/14 70% ↓, 1/14 60% ↓	Off-work period 7 (4–10)† weeks	Temporary paraesthesias in most cases
Suresh *et al* 2023[19]	59 (46–74)†; 75	N/A	60.7 (20.9–77.8)†	Complete pain resolution in 4/12, partial in 1/12	Of 3/12 with in person follow-up, 3 scores 10/10 on Kapandji	Three conversions to arthroplasty
Tuffaha *et al* 2019[20]	59 (46–74)†; 75	N/A	15 (3–28)†	Pain resolution complete in 8/12, near complete in 3/12, none in 1/12	Of 8/12 with strength measurements: Grip strength mean ↑4.1 (3.0)§ Lateral pinch strength ↑1.7 (0.5)§	Patchy numbness (8) Pin-point pain (1)
PIPJ						
Braga-Silva and Calcagnotto 2001[32]	63 (50–75)†; 86	8‡	77 (64–90)†	2‡; average ↓6	22/24 joints good improvement. RoM 67° (55–80)†; average ↑10°	Paraesthesia (5), resolved <30 days (3). Deformity increased in 3/11 deformed joints
Jiménez *et al* 2020[31]	52 (30–69)†; 36	7.8 (5–10)	24 (12–120)**	1.4 (0–3); average ↓6.4	DASH 8.7 (2.3–20.5); average ↓34.9 RoM mean 79°; average ↑27°	Transient digital paraesthesia (2)

Continued

Table 4 Continued

First Author	Patient age years (range); female sex (%)	Baseline pain	Follow-up (months)	Outcomes at follow-up		Adverse events (number of joints)
				Pain	Other	
Servasier *et al* 2021[29]	66.5 (44–78)†; 98	7.5 (5–10)†	51 (4–168)†	In 47/54 unrevised joints: average 1.1 (0–8)†; average ↓6.4	In 16/54 improved joints: mean RoM ↑13.9°‡ in flexion, ↑3.5°‡ extension	Transient skin sensitisation (1) Complex regional pain syndrome (7) Failures (7)
DIPJ						
Arenas-Prat 2012[33]	N/A; N/A	N/A	4–16*	7/10 good pain relief	7/10 pleased 1/10 unchanged 2/10 not satisfied	Necrosis of surgical area (1) Hypersensitive scar (1)
MCPJ						
Arenas-Prat 2014[35]	N/A; N/A	N/A	N/A	3/9 complete pain relief, 5/9 significant improvement, 1/9 minimal	3/9 very satisfied, 5/9 satisfied	N/A
MCPJ/DIPJ/PIPJ						
Madsen *et al* 2018[30]	57.8 (39–66)†; 55	5/5 (2–5)**	26.5 (9–46)†	0/5 (0–5)**; average ↓5	Function 2/5 (0–5) to 5/5 (1-5)**; average ↑3 Recovery time 96 (2–210)† days	Persistent numbness in overlying skin (5) Persistent fingertip numbness (1) No improvement in joint pain (1) Recurrence of pain (2)
Non-randomised clinical trial						
CMCJ-I						
Salibi *et al* 2019[23]	Arm 1: 61 (55–72)†; 50 Arm 2: 58 (41–72)‡; 83	N/A; N/A	60	Arm 1: ΔVAS pain at 6 months (0.19)‡, 12 months (0.21)‡, 60 months (0.15).‡ Arm 2: ΔVAS pain at 6 months (0.09)‡, 12 months (0.13)‡, 60 months (0.10)‡	No significant differences between groups	Denervations converted to trapeziectomy (9)

Patient characteristics and outcomes. Pain reported on a 10-point NRS, unless specified otherwise.
Arm 1: trapeziectomy; arm 2: denervation.
*Range.
†Mean (range).
‡Mean.
§Mean (SD).
¶Median (SD).
**Median (range).
††Mean (max).
CMCJ-I, First carpometacarpal joint; DASH, disability of the arm, shoulder and hand; DIPJ, distal interphalangeal joint; FU, follow-up; MCPJ, metacarpophalangeal joint; N/A, not available; NRS, Numeric Rating Scale; PIPJ, proximal interphalangeal joint; RoM, range of motion; RoM, range of motion; VAS, Visual Analogue Scale.

arose from a strong patient preference for denervation. As such, their results are likely to be biased due to among others regression to the mean and placebo effects, as well as publication bias favouring positive outcomes. In total, the current state of the literature does not allow for definitive conclusions. However, the reported results of this intervention are generally positive. Most studies showed pain reduction, high patient satisfaction and retained or improved function. The pain reduction after denervation exceeded the minimal clinical important difference for NRS pain in most studies.[41] This legitimises further evaluation in randomised clinical trials.

Conversely, adverse events were frequent, with only one study reporting no adverse events.[27] Sensory abnormalities frequently occurred, as well as postoperative infections and the need for other surgical interventions. However, the frequency and severity of adverse events after surgical denervation can currently not be assessed with certainty, as the described studies lack sufficient quality. Nine cases from the studies developed complex regional pain syndrome. This severe adverse event may be worse than hand OA, and as such should be taken seriously. Of these patients with complex regional pain syndrome, two were described to be settled with hand therapy and

analgesics (by the same authors, which may describe the same patient in two papers).[21 22] Of the remaining seven, three diagnoses were doubtful and showed swift regression of symptoms, one resolved within 6 months and three resolved within 12 months.[29] Another potential adverse event of denervation could be negative effects on the joint structure, given the concerns raised previously that removal of or interfering with pain signalling in the joint may exacerbate cartilage damage, both in clinical and basic science.[42 43] Development of Charcot joint has also been described as a potential adverse outcome of surgical denervation, but was not seen in the studies covered in this review.[9 10] The knowledge gap concerning adverse events needs to be addressed before denervation surgery can be recommended as a standard part of treatment for hand OA, as no sufficient risk-benefit analysis can be done without adequate information on adverse events. Specifically, comparisons of the adverse events after surgical denervation compared with other surgical interventions and other therapies targeting nerves are needed.

Another aspect of surgical denervation to consider is the possibility of a second surgery should the denervation fail, previously described as a strong potential benefit.[9 10 44 45] Although it may technically be possible, it is unclear whether the outcomes of such an intervention are comparable to the outcomes of the same intervention without a preceding denervation. The reviewed studies offered insufficient evidence to answer this question.

Finally, techniques employed for denervation still vary greatly between surgeons. The studies included here differed in the incisions used, in the nerves targeted for denervation and in additional interventions performed. This makes direct comparison of the results difficult, and a consensus on at least the nerves to dissect and potential additional interventions to perform should be reached. For example, Giesen *et al*[26] decided to make an extra incision to dissect the posterior interosseous nerve in addition to the nerves innervating the CMCJ-I. More uniformity in the surgical techniques may aid interpretation and evaluation of the effects of surgical denervation. The selection of the surgical techniques should be based on the innervation of the joint, and as such this innervation needs to be known.

There is an increasing understanding of the complexity of hand OA pain, which is thought to be nociceptive, but also nociplastic or neuropathic in nature, with central and peripheral sensitisation influencing it.[46] Studies in this review did not assess the type of hand pain. So, it is currently unknown for which type of hand pain surgical denervation might be beneficial. This lack of results stratified by pain phenotype needs to be addressed in future studies.

In conclusion, we currently cannot be sure the benefits of surgical denervation outweigh the harms to treat patients with hand OA, given the small number of cases and overall low quality of the evidence. Thus, we do not recommend denervation surgery for pain relief in hand OA. However, the available results indicate the outcomes may be favourable, although a considerable number of complications were reported. To further evaluate the use of surgical denervation in hand OA, we propose future studies should investigate (1) the innervation of the joints, (2) the best surgical technique to dissect all relevant nerves, (3) perform high-quality randomised clinical trials to investigate the efficacy of surgical denervation in comparison to sham in different patient groups, (4) to investigate other (non-surgical) therapies targeting the nerves, and finally (5) the safety of surgical denervation.

Author affiliations
[1]Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
[2]Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands
[3]Dutch Society for Rheumatology, Utrecht, The Netherlands
[4]Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands
[5]Department of Plastic, Reconstructive and Hand Surgery, Amsterdam University Medical Centres, Amsterdam, The Netherlands
[6]Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
[7]Department of Orthopaedics, OCON Orthopedische kliniek, Hengelo, The Netherlands

Twitter Sietse E S Terpstra @OAKloppenburg

Acknowledgements We would like to thank the working group for the Dutch recommendations for the management of hand osteoarthritis.

Contributors MK, AC, MJPFR and AJHV designed the study. CvdM, AC, SEST and MK collected the data. CM, LAvdS and MK analysed the data. CvdM, LAvdS, AC, FPBK, MJPFR, FRR, SEST, AJHV and MK interpreted the data and wrote the report. All authors approved the final version of the manuscript. CvdM is the guarantor of this manuscript.

Funding For the current study, MK reports funding from the SKMS, paid to the institution.

Competing interests MK reports the following, all outside the current study: Grants from IMI-APPROACH and the Dutch Arthritis Society, paid to the institution. Royalties or licences from Wolters Kluwer and Springer Verlag, paid to the institution. Fees for consulting/advisory boards by Abbvie, Kiniksa, Galapagos, CHDR, Novartis, UCB, all paid to the institution. Payment or honoraria for lectures or presentations from Galapagos and Jansen, paid to the institution. Roles on the OARSI board (member), EULAR council (member advocacy committee EULAR) and presidency of the Dutch Society for Rheumatology. For the current study, MK reports funding from SKMS, paid to the institution.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to the study are included in the article or uploaded as supplementary information. The used search strategies are shown in the supplementary file and can be used to reproduce the search.

ORCID iDs
Coen van der Meulen http://orcid.org/0000-0002-6624-3246
Féline P B Kroon http://orcid.org/0000-0002-8940-0582
Sietse E S Terpstra http://orcid.org/0000-0001-8345-6297

REFERENCES

1 Kloppenburg M, Kwok W-Y. Hand osteoarthritis--a heterogeneous disorder. *Nat Rev Rheumatol* 2011;8:22–31.
2 Marshall M, Watt FE, Vincent TL, *et al*. Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. *Nat Rev Rheumatol* 2018;14:641–56.
3 Kolasinski SL, Neogi T, Hochberg MC, *et al*. American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* 2020;72:149–62.
4 Kloppenburg M, Kroon FP, Blanco FJ, *et al*. Update of the Eular recommendations for the management of hand osteoarthritis. *Ann Rheum Dis* 2019;78:16–24.
5 Tieman TE, Duraku LS, van der Oest MJW, *et al*. Denervation of the joints of the hand and wrist: surgical techniques and a systematic review with meta-analysis. *Plast Reconstr Surg* 2021;148:959e–72e.
6 Tavernier L. Surgical treatment of degenerative arthritis of the hip; articular denervation. *Rheumatism* 1948;4:176–9.
7 Wilhelm A. Denervation of the wrist. *Tech Hand Up Extrem Surg* 2001;5:14–30.
8 Wu CH, Strauch RJ. Wrist Denervation: techniques and outcomes. *Orthop Clin North Am* 2019;50:345–56.
9 Zhu SL, Chin B, Sarraj M, *et al*. Denervation as a treatment for arthritis of the hands: a systematic review of the current literature. *Hand (New York, N,Y)* 2023;18:183–91.
10 Gandolfi S, Carloni R, Mouton J, *et al*. Finger joint denervation in hand osteoarthritis: indications, surgical techniques and outcomes. A systematic review of published cases. *Hand Surg Rehabil* 2020;39:239–50.
11 Gandolfi S, Auquit-Auckbur I, Chaput B, *et al*. Innervation of digital joints: an anatomical overview. *Surg Radiol Anat* 2021;43:1635–46.
12 Gray DJ, Gardner E. The Innervation of the joints of the wrist and hand. *Anat Rec* 1965;151:261–6.
13 Kim YS. Innervation of metacarpophalangeal joint and distal interphalangeal joint: an anatomical and histological study. *Kaibogaku Zasshi* 2001;76:313–22.
14 Chen YG, McClinton MA, DaSilva MF, *et al*. Innervation of the metacarpophalangeal and interphalangeal joints: a microanatomic and histologic study of the nerve endings. *J Hand Surg Am* 2000;25:128–33.
15 Paulsen F, Waschke J. *Sobotta Atlas of Human Anatomy, Vol.1, 15th Ed., English*. Munich: Elsevier, 2013.
16 Munn Z, Barker TH, Moola S, *et al*. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. *JBI Evid Synth* 2020;18:2127–33.
17 Sterne JA, Hernán MA, Reeves BC, *et al*. Robins-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016:i4919.
18 Group OLoEW. The Oxford 2011 levels of evidence: Oxford centre for evidence-based medicine. 2011. Available: http://www.cebm.net/index.aspx?o=5653
19 Suresh V, Frost CM, Lifchez SD. Selective thumb carpometacarpal joint denervation for painful arthritis: follow-up of long-term clinical outcomes. *J Hand Surg Glob Online* 2023;5:108–11.
20 Tuffaha SH, Quan A, Hashemi S, *et al*. Selective thumb carpometacarpal joint denervation for painful arthritis: clinical outcomes and cadaveric study. *J Hand Surg Am* 2019;44:64.
21 Ehrl D, Erne HC, Broer PN, *et al*. Painful thumb carpometacarpal joint osteoarthritis: results of a novel treatment approach. *J Plast Reconstr Aesthet Surg* 2016;69:972–6.
22 Ehrl D, Erne HC, Broer PN, *et al*. Outcomes of denervation, joint lavage and capsular imbrication for painful thumb carpometacarpal joint osteoarthritis. *J Hand Surg Eur Vol* 2016;41:904–9.
23 Salibi A, Hilliam R, Burke FD, *et al*. Prospective clinical trial comparing trapezial denervation with trapeziectomy for the surgical treatment of arthritis at the base of the thumb. *J Surg Res* 2019;238:144–51.
24 Donato D, Abunimer AM, Abou-Al-Shaar H, *et al*. First carpometacarpal joint denervation for primary osteoarthritis: technique and outcomes. *World Neurosurg* 2019;122:e1374–80.
25 Loréa PD. First carpometacarpal joint denervation: anatomy and surgical technique. *Tech Hand Up Extrem Surg* 2003;7:26–31.
26 Giesen T, Klein HJ, Franchi A, *et al*. Thumb carpometacarpal joint denervation for primary osteoarthritis: a prospective study of 31 thumbs. *Hand Surg Rehabil* 2017;36:192–7.
27 Dellon AL. Volar denervation and osteophyte resection to relieve Volar CMC joint pain. *Case Reports Plast Surg Hand Surg* 2017;4:13–6.
28 Arenas-Prat J. Denervation with periosteal resection of the first carpometacarpal joint. *Tech Hand Up Extrem Surg* 2022;26:229–31.
29 Servasier L, Laulan J, Marteau E, *et al*. Denervation of the proximal interphalangeal joint: results from 54 cases in 42 patients. *Orthop Traumatol Surg Res* 2021;107:102976.
30 Madsen RJ, Stone LA, Knapp JB, *et al*. Joint denervation in the digits: technique and patient satisfaction. *Ann Plast Surg* 2018;80:27–31.
31 Jiménez I, Marcos-García A, Muratore G, *et al*. Denervation for proximal interphalangeal joint osteoarthritis. *J Hand Surg Am* 2020;45:358.
32 Braga-Silva J, Calcagnotto G. The Innervation of the proximal interphalangeal joint and its application in neurectomy. *J Hand Surg Br* 2001;26:541–3.
33 Arenas-Prat JM. Denervation of the distal Interphalangeal joint. *Tech Hand Up Extrem Surg* 2012;16:12–3.
34 Arenas-Prat JM. Wagner approach for first carpometacarpal joint denervation. *Tech Hand Up Extrem Surg* 2012;16:107–9.
35 Arenas-Prat J. Denervation of the metacarpophalangeal joint. *Tech Hand Up Extrem Surg* 2014;18:158–9.
36 Radnovich R, Scott D, Patel AT, *et al*. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. *Osteoarthr Cartil* 2017;25:1247–56.
37 Choi W-J, Hwang S-J, Song J-G, *et al*. Radiofrequency treatment relieves chronic knee osteoarthritis pain: a double-blind randomized controlled trial. *Pain* 2011;152:481–7.
38 Davis T, Loudermilk E, DePalma M, *et al*. Prospective, multicenter, randomized, crossover clinical trial comparing the safety and effectiveness of cooled radiofrequency ablation with corticosteroid injection in the management of knee pain from osteoarthritis. *Reg Anesth Pain Med* 2018;43:84–91.
39 Shen WS, Xu XQ, Zhai NN, *et al*. Radiofrequency thermocoagulation in relieving refractory pain of knee osteoarthritis. *Am J Ther* 2017;24:e693–700.
40 El-Hakeim EH, Elawamy A, Kamel EZ, *et al*. Fluoroscopic guided radiofrequency of genicular nerves for pain alleviation in chronic knee osteoarthritis: a single-blind randomized controlled trial. *Pain Physician* 2018;21:169–77.
41 Salaffi F, Stancati A, Silvestri CA, *et al*. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. *Eur J Pain* 2004;8:283–91.
42 Neogi T, Hunter DJ, Churchill M, *et al*. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous Tanezumab: results from a 56-week randomized NSAID-controlled study. *Arthritis Res Ther* 2022;24:78.
43 Wang L, Ishihara S, Li J, *et al*. Op0195 targeted ablation of knee-Innervating nociceptors has profound effects on joint damage in experimental osteoarthritis. *Ann Rheum Dis* 2023;82:129.
44 Teo I, Riley N. Thumb carpometacarpal joint osteoarthritis: is there a role for denervation? A systematic review. *J Plast Reconstr Aesthet Surg* 2020;73:1208–20.
45 Stögner V-A, Krezdorn N, Vogt PM. “Comment on: "Thumb carpometacarpal joint osteoarthritis: is there a role for denervation? A systematic review"” *J Plast Reconstr Aesthet Surg* 2021;74:1101–60.
46 Serge P, Anne-Priscille T. Pain in osteoarthritis from a symptom to a disease. *Best Pract Res Clin Rheumatol* 2023:101825.